Mayo Clinic today unveiled separate groundbreaking collaborations with Microsoft Research and with Cerebras Systems in the field of generative artificial intelligence (AI), designed to personalize ...
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling ...
NDAQ:VRTX) Lost Money on Vertex Pharmaceuticals Incorporated (VRTX)? You May Have Been Affected by Fraud - Contact Levi & ...
Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report)‘s stock had its “outperform” rating reaffirmed by stock analysts at ...
I last wrote here several months ago about the sodium channel (NaV1.8) inhibitor VX-548 (now known as suzetrigine), which is ...
Hosted on MSN2d
Verismo doses first subject in Phase I trial of SynKIR-310The subject was dosed at the Sarah Cannon Research Institute of Colorado Blood Cancer Institute in Denver, Colorado.
A non-opioid painkiller from Vertex Pharmaceuticals could become a blockbuster, but questions remain on whether it will prove ...
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) 43rd Annual J.P. Morgan Healthcare Conference January 13, 2025 10:30 AM ETCompany ParticipantsDr.
Regulatory complexity isn’t the only challenges clinical services organizations face in the APAC market. Cheong points to ...
Continue advancing our pipeline candidates, with several key updates in 2025, including CTX112™ in oncology and autoimmune ...
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced multiple program updates ahead of upcoming investor ...
In the latest market close, Vertex Pharmaceuticals (VRTX) reached $409.56, with a -0.62% movement compared to the previous day. This change was narrower than the S&P 500's 1.54% loss on the day.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback